Business News • PR NewsWire • Data Presented at American Society of Hematology from Ibrutinib Phase 1b/2 and Phase 2 Trials Suggest High and Durable Response in Chronic Lymphocytic Leukemia

Data Presented at American Society of Hematology from Ibrutinib Phase 1b/2 and Phase 2 Trials Suggest High and Durable Response in Chronic Lymphocytic Leukemia

Data Presented at American Society of Hematology from Ibrutinib Phase 1b/2 and Phase 2 Trials Suggest High and Durable Response in Chronic Lymphocytic Leukemia

ATLANTA, Dec. 8, 2012 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced follow-up results that its investigational oral therapy ibrutinib (PCI-32765), as a single agent, resulted in durable responses for patients over 65 years of age with treatment-naive chronic...

View More : http://www.prnewswire.com/news-releases/data-presented-at-american-society-of-hematology-from-ibrutinib-phase-1b2-and-ph...

Releted News by prnewswire

Dassault Falcon Expands Middle East Sales Team

Studies Assess Role of Genetics, Modified Treatment Strategies to Improve Outcomes and Reduce Toxicity for Patients with Blood Cancers

Halozyme Announced Roche Filed A Marketing Authorization Application For Subcutaneous MabThera

Data Presented at American Society of Hematology from Ibrutinib Phase 1b/2 and Phase 2 Trials Suggest High and Durable Response in Chronic Lymphocytic Leukemia